Downloads
Abstract
Objectives: To evaluate the treatment outcomes and toxicities of the induction chemotherapy with Docetaxel - Cisplatin - 5 Fluorouracil (TPF) regimen in stage III - IVA nasopharyngeal carcinoma.
Methods: A combined descriptive study of prospective and retrospective was conducted on thirty - four eligible stage III - IVA nasopharyngeal carcinoma patients treated with induction chemotherapy regimen TPF in Hue Central Hospital between 11/2019 and 6/2022, follow - up until 6/2023.
Results: Median age 46.7 ± 13.1, male/female ratio 2.8/1. Stage IVA patients were dominant with 61.8%, while stage III patients were 38.2%. The subjective response rate after induction chemotherapy was 97.1%. The overall response rate was 88.2%, with 17.6% complete response and 70.6% partial response. The progression - free survival rate at 1 year was 88.2%. The overall survival rate at 1 year was 94.1%. Common toxicities comprised neutropenia 50% (grade III - IV 11.8%, febrile neutropenia 0%), diarrhea 32.4% (grade III 5.9%), nausea, vomiting 55.9% (grade III-IV 0%), alopecia 88.2%, and no treatment - related deaths.
Conclusion: TPF regimen achieved highly effective treatment outcome in stage III - IVA nasopharyngeal carcinoma with manageable toxicity.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
Global Cancer Vietnam 2020 fact sheets [Internet]. [cited 2023 Jul 1]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf
Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients? Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8.
Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal
carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012 Feb 1;13(2):163-71.
Lee AWM, Ngan RKC, Ng WT, Tung SY, Cheng AAC, Kwong DLW, et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer. 2020;126(16):3674-88.
Petit C, Lee AW, Carmel A, Ng WT, Ma J, Chan AT, et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients. J Clin Oncol. 2020 May 20;38(15_suppl):6523-6523.
Trịnh Lê Huy, Nguyễn Văn Vinh. Kết quả sớm xạ trị điều biến liều kết hợp hóa trị đồng thời ung thư vòm mũi họng giai đoạn III-IVA. Tạp Chí Học Việt Nam. 2022 Apr 15;511(1):194-198.
Nguyễn Văn Tài, Đỗ Hùng Kiên. Đánh giá kết quả bước đầu hoá chất tân bổ trợ phác đồ TCF trên bệnh nhân ung thư vòm giai đoạn III-IVA tại Bệnh viện K – Tạp chí Ung Thư học Việt Nam. 2022(2):52-58.
Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. (2) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-20.
Zhu J, Duan B, Shi H, Li Y, Ai P, Tian J, et al. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2019 Oct 1;97:37-43.
| Published | 26-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 91 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.91.6 | |
| Keywords | Ung thư vòm, giai đoạn III-IVA, hóa trị gây đáp ứng, TPF, độc tính Nasopharyngeal carcinoma, stage III - IVA, induction chemotherapy, TPF, toxicity |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital